68Ga-DOTA-DiPSMA PET/CT Imaging: Biodistribution, Dosimetry, and Preliminary Application in Prostate Cancer
Purpose: This prospective trial aimed to evaluate the safety, dosimetry, and biodistribution of a novel theranostic probe 68Ga-DOTA-DiPSMA. Also, we have performed the first preliminary application with 68Ga-DOTA-DiPSMA in prostate cancer (PCa) patients.Methods: Five healthy volunteers and ten PCa p...
Main Authors: | Jiaying Zhang, Zefang Lin, Xiaojun Zhang, Rong Lin, Mengchao Cui, Weibing Miao, Shaobo Yao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-01-01
|
Series: | Frontiers in Bioengineering and Biotechnology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2021.811972/full |
Similar Items
-
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
by: Hongmei Li, et al.
Published: (2024-03-01) -
Preparation and biological studies of 68Ga-DOTA-alendronate
by: Ashraf Fakhari, et al.
Published: (2016-07-01) -
Preparation and Preliminary Imaging of Novel Albumin-Binding PSMA Ligand [177Lu]Lu-DOTA-CPN-PSMA
by: LUO Tian-wei, et al.
Published: (2023-12-01) -
Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
by: Frederik A. Verburg, et al.
Published: (2023-11-01) -
Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer
by: Melanie Hohberg, et al.
Published: (2019-07-01)